Intravenous Immunoglobulin Market By Indication and End User- Global Industry Analysis & Forecast to 2027
Published On : November 2018 Pages : 140 Category: Pharmaceuticals Report Code : HC111825
Intravenous Immunoglobulin Market By Indication (Primary Humoral Immunodeficiency, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Idiopathic Thrombocytopenic Purpura, Myasthenia Gravis, Kawasaki Disease and Chronic Lymphocytic Leukemia) and End User (Clinics, Hospitals and Home Care) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
Intravenous Immunoglobulin therapies are also known as IVIG therapies are used for treating immunodeficiency diseases and are regarded as the most appropriate treatment option in the present times and thus are gaining popularity. While the factors like low physical activities, more consumption of salt and sugar, high consumption of alcohol and prevalence of other diseases play a major role in creating health issues within the humans which leads to deficiency disorders. These therapies are regarded as a revolutionary step in the medical sector.
Drivers and Restraints
The Intravenous Immunoglobulin market is growing on the global basis due to the rising cases of autoimmune diseases like PIDD, multiple sclerosis, ITP and Kawasaki syndrome. The various advancements taking place in the medical sector also boosts the market majorly. Rise in the geriatric population and neurological disorders increases the need for reliable treatment options is an encouraging factor while the complexity and faith in the traditional treatment options creates a barrier for the market.
Regional Insights
The largest share of the market is held by North America due to the use of advanced digital services and devices in the medical sector. European region also consumes a large part of the market and is depicting a strong growth while the Asian region also has a great potential to grow during the forecast period.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- ADMA Biologics, Inc.
- CSL Behring LLC
- Kedrion S.p.A.
- Octapharma AG
- Shire plc.
- China Biologic Products Inc.
- Grifols S.A.
- LFB Biomedicaments S.A.
- Sanquin Plasma Products B.V.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Intravenous Immunoglobulin Market, By Indication, Estimates and Forecast, 2017-2027 ($Million)
o Primary Humoral Immunodeficiency
o Guillain-Barre Syndrome
o Multifocal Motor Neuropathy
o Hypogammaglobulinemia
o Chronic Inflammatory Demyelinating Polyneuropathy
o Idiopathic Thrombocytopenic Purpura
o Myasthenia Gravis
o Kawasaki Disease
o Chronic Lymphocytic Leukemia
· Intravenous Immunoglobulin Market, By End User, Estimates and Forecast, 2017-2027 ($Million)
o Clinics
o Hospitals
o Home Care
· Intravenous Immunoglobulin Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Intravenous Immunoglobulin market, By Country
o U.S. Intravenous Immunoglobulin market
o Canada Intravenous Immunoglobulin market
o Mexico Intravenous Immunoglobulin market
o Europe
§ Europe Intravenous Immunoglobulin market, By Country
o Germany Intravenous Immunoglobulin market
o UK Intravenous Immunoglobulin market
o France Intravenous Immunoglobulin market
o Russia Intravenous Immunoglobulin market
o Italy Intravenous Immunoglobulin market
o Rest of Europe Intravenous Immunoglobulin market
o Asia-Pacific
§ Asia-Pacific Intravenous Immunoglobulin market, By Country
o China Intravenous Immunoglobulin market
o Japan Intravenous Immunoglobulin market
o South Korea Intravenous Immunoglobulin market
o India Intravenous Immunoglobulin market
o Southeast Asia Intravenous Immunoglobulin market
o Rest of Asia-Pacific Intravenous Immunoglobulin market
o South America
§ South America Intravenous Immunoglobulin market
o Brazil Intravenous Immunoglobulin market
o Argentina Intravenous Immunoglobulin market
o Columbia Intravenous Immunoglobulin market
o Rest of South America Intravenous Immunoglobulin market
o Middle East and Africa
§ Middle East and Africa Intravenous Immunoglobulin market
o Saudi Arabia Intravenous Immunoglobulin market
o UAE Intravenous Immunoglobulin market
o Egypt Intravenous Immunoglobulin market
o Nigeria Intravenous Immunoglobulin market
o South Africa Intravenous Immunoglobulin market
o Rest of MEA Intravenous Immunoglobulin market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Intravenous Immunoglobulin Market, By Indication
5.1. Introduction
5.2. Global Intravenous Immunoglobulin Revenue and Market Share by Indication (2017-2027)
5.2.1. Global Intravenous Immunoglobulin Revenue and Revenue Share by Indication (2017-2027)
5.3. Primary Humoral Immunodeficiency
5.3.1. Global Primary Humoral Immunodeficiency Revenue and Growth Rate (2017-2027)
5.4. Guillain-Barre Syndrome
5.4.1. Global Guillain-Barre Syndrome Revenue and Growth Rate (2017-2027)
5.5. Multifocal Motor Neuropathy
5.5.1. Global Multifocal Motor Neuropathy Revenue and Growth Rate (2017-2027)
5.6. Hypogammaglobulinemia
5.6.1. Global Hypogammaglobulinemia Revenue and Growth Rate (2017-2027)
5.7. Chronic Inflammatory Demyelinating Polyneuropathy
5.7.1. Global Chronic Inflammatory Demyelinating Polyneuropathy Revenue and Growth Rate (2017-2027)
5.8. Idiopathic Thrombocytopenic Purpura
5.8.1. Global Idiopathic Thrombocytopenic Purpura Revenue and Growth Rate (2017-2027)
5.9. Myasthenia Gravis
5.9.1. Global Myasthenia Gravis Revenue and Growth Rate (2017-2027)
5.10. Kawasaki Disease
5.10.1. Global Kawasaki Disease Revenue and Growth Rate (2017-2027)
5.11. Chronic Lymphocytic Leukemia
5.11.1. Global Chronic Lymphocytic Leukemia Revenue and Growth Rate (2017-2027)
6. Intravenous Immunoglobulin Market, By End User
6.1. Introduction
6.2. Global Intravenous Immunoglobulin Revenue and Market Share by End User (2017-2027)
6.2.1. Global Intravenous Immunoglobulin Revenue and Revenue Share by End User (2017-2027)
6.3. Clinics
6.3.1. Global Clinics Revenue and Growth Rate (2017-2027)
6.4. Hospitals
6.4.1. Global Hospitals Revenue and Growth Rate (2017-2027)
6.5. Home Care
6.5.1. Global Home Care Revenue and Growth Rate (2017-2027)
7. Intravenous Immunoglobulin Market, By Region
7.1. Introduction
7.2. Global Intravenous Immunoglobulin Revenue and Market Share by Regions
7.2.1. Global Intravenous Immunoglobulin Revenue by Regions (2017-2027)
7.3. North America Intravenous Immunoglobulin by Countries
7.3.1. North America Intravenous Immunoglobulin Revenue and Growth Rate (2017-2027)
7.3.2. North America Intravenous Immunoglobulin Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Intravenous Immunoglobulin by Countries
7.4.1. Europe Intravenous Immunoglobulin Revenue and Growth Rate (2017-2027)
7.4.2. Europe Intravenous Immunoglobulin Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Intravenous Immunoglobulin by Countries
7.5.1. Asia-Pacific Intravenous Immunoglobulin Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Intravenous Immunoglobulin Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Intravenous Immunoglobulin by Countries
7.6.1. South America Intravenous Immunoglobulin Revenue and Growth Rate (2017-2027)
7.6.2. South America Intravenous Immunoglobulin Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Intravenous Immunoglobulin by Countries
7.7.1. Middle East and Africa Intravenous Immunoglobulin Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Intravenous Immunoglobulin Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. ADMA Biologics, Inc.
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Revenue and Market Share
8.2. CSL Behring LLC
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Revenue and Market Share
8.3. Kedrion S.p.A.
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Revenue and Market Share
8.4. Octapharma AG
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Revenue and Market Share
8.5. Shire plc
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Revenue and Market Share
8.6. China Biologic Products Inc.
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Revenue and Market Share
8.7. Grifols S.A.
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Revenue and Market Share
8.8. LFB Biomedicaments S.A.
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Revenue and Market Share
8.9. Sanquin Plasma Products B.V.
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Revenue and Market Share
9. Global Intravenous Immunoglobulin Market Competition, by Manufacturer
9.1. Global Intravenous Immunoglobulin Revenue and Market Share by Manufacturer (2017-2017)
9.2. Global Intravenous Immunoglobulin Price By Region (2017-2017)
9.3. Top 5 Intravenous Immunoglobulin Manufacturer Market Share
9.4. Market Competition Trend
10. Intravenous Immunoglobulin Market Forecast (2017-2027)
10.1. Global Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2027)
10.2. Intravenous Immunoglobulin Market Forecast by Regions (2017-2027)
10.2.1. North America Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.1.1. United States Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.1.2. Canada Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.1.3. Mexico Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.2. Europe Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.2.1. Germany Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.2.2. France Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.2.3. UK Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.2.4. Russia Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.2.5. Italy Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.2.6. Rest of Europe Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.3. Asia-Pacific Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.3.1. China Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.3.2. Japan Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.3.3. Korea Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.3.4. India Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.3.5. Southeast Asia Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.3.6. Rest of Asia-Pacific Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.4. South America Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.4.1. Brazil Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.4.2. Argentina Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.4.3. Columbia Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.4.4. Rest of South America Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.5. Middle East and Africa Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.5.1. Saudi Arabia Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.5.2. United Arab Emirates Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.5.3. Egypt Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.5.4. Nigeria Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.5.5. South Africa Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.5.6. Turkey Intravenous Immunoglobulin Market Forecast (2017-2027)
10.2.5.7. Rest of Middle East and Africa Intravenous Immunoglobulin Market Forecast (2017-2027)
10.3. Intravenous Immunoglobulin Market Forecast by Indication (2017-2027)
10.3.1. Intravenous Immunoglobulin Forecast by Indication (2017-2027)
10.3.2. Intravenous Immunoglobulin Market Share Forecast by Indication (2017-2027)
10.4. Intravenous Immunoglobulin Market Forecast by End User (2017-2027)
10.4.1. Intravenous Immunoglobulin Forecast by End User (2017-2027)
10.4.2. Intravenous Immunoglobulin Market Share Forecast by End User (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Intravenous Immunoglobulin Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Intravenous Immunoglobulin Revenue and Revenue Share by Indication (2017-2018)
Figure Global Primary Humoral Immunodeficiency Revenue and Growth Rate (2017-2018)
Figure Global Guillain-Barre Syndrome Revenue and Growth Rate (2017-2018)
Figure Global Multifocal Motor Neuropathy Revenue and Growth Rate (2017-2018)
Figure Global Hypogammaglobulinemia Revenue and Growth Rate (2017-2018)
Figure Global Chronic Inflammatory Demyelinating Polyneuropathy Revenue and Growth Rate (2017-2018)
Figure Global Idiopathic Thrombocytopenic Purpura Revenue and Growth Rate (2017-2018)
Figure Global Myasthenia Gravis Revenue and Growth Rate (2017-2018)
Figure Global Kawasaki Disease Revenue and Growth Rate (2017-2018)
Figure Global Chronic Lymphocytic Leukemia Revenue and Growth Rate (2017-2018)
Table Global Intravenous Immunoglobulin Revenue and Revenue Share by End User (2017-2018)
Figure Global Clinics Revenue and Growth Rate (2017-2018)
Figure Global Hospitals Revenue and Growth Rate (2017-2018)
Figure Global Home Care Revenue and Growth Rate (2017-2018)
Table Global Intravenous Immunoglobulin Revenue by Regions (2017-2018)
Figure North America Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure North America Intravenous Immunoglobulin Revenue and Growth Rate (2017-2018)
Figure North America Intravenous Immunoglobulin by Countries (2017-2018)
Figure North America Intravenous Immunoglobulin Revenue (Million USD) by Countries (2017-2018)
Figure United States Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure United States Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Canada Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Mexico Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Europe Intravenous Immunoglobulin Revenue and Growth Rate (2017-2018)
Figure Europe Intravenous Immunoglobulin by Countries (2017-2018)
Figure Europe Intravenous Immunoglobulin Revenue (Million USD) by Countries (2017-2018)
Figure Germany Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Germany Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure France Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure UK Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Russia Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Italy Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Rest of Europe Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Asia-Pacific Intravenous Immunoglobulin Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Intravenous Immunoglobulin by Countries (2017-2018)
Figure Asia-Pacific Intravenous Immunoglobulin Revenue (Million USD) by Countries (2017-2018)
Figure China Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure China Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Japan Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Korea Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure India Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Southeast Asia Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure South America Intravenous Immunoglobulin Revenue and Growth Rate (2017-2018)
Figure South America Intravenous Immunoglobulin by Countries (2017-2018)
Figure South America Intravenous Immunoglobulin Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Brazil Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Argentina Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Columbia Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Rest of South America Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Middle East and Africa Intravenous Immunoglobulin Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Intravenous Immunoglobulin by Countries (2017-2018)
Figure Middle East and Africa Intravenous Immunoglobulin Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Saudi Arabia Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure United Arab Emirates Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Egypt Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Nigeria Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure South Africa Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Turkey Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Intravenous Immunoglobulin Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2017-2018)
Table ADMA Biologics, Inc. Intravenous Immunoglobulin Price, Revenue, Gross Margin and Market Share (2017-2017)
Table CSL Behring LLC Intravenous Immunoglobulin Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Kedrion S.p.A. Intravenous Immunoglobulin Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Octapharma AG Intravenous Immunoglobulin Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Shire plc Intravenous Immunoglobulin Price, Revenue, Gross Margin and Market Share (2017-2017)
Table China Biologic Products Inc. Intravenous Immunoglobulin Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Grifols S.A. Intravenous Immunoglobulin Price, Revenue, Gross Margin and Market Share (2017-2017)
Table LFB Biomedicaments S.A. Intravenous Immunoglobulin Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Sanquin Plasma Products B.V. Intravenous Immunoglobulin Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Intravenous Immunoglobulin Market Share by Manufacturer
Figure Global Intravenous Immunoglobulin Revenue and Market Share by Manufacturer
Table Global Intravenous Immunoglobulin Price by Region (2017-2017)
Figure Top 5 Intravenous Immunoglobulin Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Intravenous Immunoglobulin Revenue (Millions USD) and Growth Rate (2018-2025)
Table Intravenous Immunoglobulin Market Forecast by Regions (2018-2025)
Figure North America Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure United States Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Canada Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Mexico Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Europe Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Germany Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure France Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure UK Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Russia Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Italy Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Rest of Europe Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Asia-Pacific Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure China Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Japan Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Korea Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure India Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Southeast Asia Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure South America Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Brazil Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Argentina Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Columbia Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Rest of South America Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Middle East and Africa Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Saudi Arabia Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure United Arab Emirates Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Egypt Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Nigeria Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure South Africa Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Turkey Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Intravenous Immunoglobulin Market Forecast (2018-2025)
Figure Global Intravenous Immunoglobulin Forecast by Indication (2018-2025)
Figure Global Intravenous Immunoglobulin Market Share Forecast by Indication (2018-2025)
Figure Global Intravenous Immunoglobulin Forecast by Indication (2018-2025)
Figure Global Intravenous Immunoglobulin Forecast by End User (2018-2025)
Figure Global Intravenous Immunoglobulin Market Share Forecast by End User (2018-2025)
Figure Global Intravenous Immunoglobulin Forecast by End User (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|